Predicting Response to Radiotherapy in Breast Cancer-Induced Bone Pain: Relationship Between Pain and Serum Cytokine Expression Levels After Radiotherapy
Yaling Lou,Henbin Cao,Ronghua Wang,Yu Chen,Haibing Zhang
DOI: https://doi.org/10.2147/JPR.S387670
IF: 2.8319
2022-11-11
Journal of Pain Research
Abstract:Yaling Lou, 1 Henbin Cao, 1 Ronghua Wang, 1 Yu Chen, 2 Haibing Zhang 3 1 Department of Clinical Pharmacy, Huzhou Central Hospital, Huzhou, People's Republic of China; 2 Department of Clinical Laboratory, Huzhou Central Hospital, Huzhou, People's Republic of China; 3 Department of Radiotherapy Center, Huzhou Central Hospital, Huzhou, People's Republic of China Correspondence: Yaling Lou; Haibing Zhang, Email ; Introduction: Breast cancer is the second leading cause of cancer-associated death in women. Herein, we explored the associations of cytokines, pain, and bone metastasis between patients before and after radiotherapy in breast cancer with bone metastasis. The pain caused by metastasis was effectively relieved by external radiation therapy. However, the underlying mechanisms remain unknown. Methods and Results: In this case-controlled study, we enrolled healthy individuals (n = 10) and bone metastatic cancer patients (n = 30). Peripheral venous blood samples were collected from healthy controls, and one week before and after radiotherapy, the peripheral venous blood and clinical characteristics of cancer patients were collected. We analyzed the blood cytokine profile, quality of life (QOL), and pain score of patients pre- and post-radiotherapy to explore the possible causes of pain relief. Both the pain score and QOL significantly improved after radiotherapy. The serum cytokine profiles of patients were significantly different before radiotherapy than after. Meanwhile, only three cytokines differed between post-radiotherapy and healthy controls. We believe radiotherapy stimulated local immune storms in bone tissue and promoted significant changes in cytokines pre- and post-radiotherapy. Therefore, the bone microenvironment of early breast cancer patients with bone metastasis pain can be restored after radiotherapy. Restoring a healthy bone environment can not only relieve the pain but also improve the patient's QOL. Conclusion: Tumor cells can effectively activate immune cells in the bone microenvironment through direct interaction, releasing many factors and promoting bone metastasis. Early local radiotherapy of bone metastases can restore the microenvironment and improve the QOL and prognosis of patients, thereby comprehending a novel target for prevention, treatment, and therapy of bone metastases. Keywords: breast cancer, bone metastasis, radiotherapy, cytokines, pain, QOL, microenvironment, immune system Breast cancer is the second leading cause of cancer-associated death in women, with 2.3 million new cases reported in 2020 worldwide. 1 In the United States, 279,100 new cases and 42,690 deaths were reported in 2020. Based on the statistics provided by the Cancer Statistics Bureau, breast cancer is the most common cancer in women (accounting for 30% of female cases) and the second cause of cancer-associated death (accounting for 15% of female cancer deaths). 2 Bone metastasis is frequently observed in breast cancer patients, with the spine, ribs, pelvis, and long bones being the most common sites. 3 Bone metastases often lead to bone-related problems, including spinal cord compression, bone marrow regeneration disorders, hypercalcemia, pain, and pathological fractures. The median time from the diagnosis to the first occurrence of bone-related events in breast cancer patients with bone metastases is only 1.8 months, and the 1-year incidence of SREs is as high as 40%. 4 Therefore, bone adverse events negatively impact the survival, activity, and quality of life (QOL) of patients, posing a significant threat to women's health. Due to the constant and dynamic reshaping of bone tissue throughout life, the occurrence and progression of bone metastases is a complex process. Under physiological conditions, the crosstalks between osteoblasts and osteoclasts at the molecular level are significantly required for bone remodeling. For example, the differentiation of osteoclasts is significantly controlled by the signals provided by osteocytes and osteoblasts through the soluble or membrane-bound RANKL. By directly binding to the RANK receptor, RANKL can promote maturation and regulate the function of osteoclasts. Osteoclast differentiation can also be negatively mediated via another soluble decoy RANKL receptor secreted by osteoblasts, osteoprotegerin (OPG). In contrast, osteoclasts affect the differentiation and activity of osteoblasts by secreting semaphorin 4D (Sema 4D) and other factors. 5 Furthermore, osteoclast and osteoblast functions can be significantly regulated by bone matrix-secreted cytokines, including insulin-like growth factor-1 (IGF-1) and TGF-β. 6 Bone remodeling imbalance is dramatically a -Abstract Truncated-
clinical neurology